User profiles for S Aebi

Stefan Aebi

Medical Oncology, Cancer Center Lucerne Cantonal Hospital, and University of Berne
Verified email at onkologie.ch
Cited by 10839

[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …

…, MM Regan, HJ Senn, EP Winer, M Gnant, S Aebi… - Annals of oncology, 2021 - Elsevier
… However, the Panel strongly favored RNI for patients who initially presented with a clinically
positive axillary node(s), even when such patients achieve a pCR with neoadjuvant therapy. …

The role of DNA mismatch repair in drug resistance.

D Fink, S Aebi, SB Howell - Clinical cancer research: an official journal of the …, 1998 - AACR
Loss of DNA mismatch repair (MMR) has been observed in a variety of human cancers. In
addition to predisposing to oncogenesis, loss of MMR activity is of concern with respect to the …

Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?

S Aebi, S Gelber, M Castiglione-Gertsch, RD Gelber… - The Lancet, 2000 - thelancet.com
S Gelber and RD Gelber were responsible or the statistical analysis. J Collins was the
chairman of … S Aebi wrote the first draft of the report. All investigators read and edited the report. …

The role of DNA mismatch repair in platinum drug resistance

D Fink, S Nebel, S Aebi, H Zheng, B Cenni, A Nehmé… - Cancer research, 1996 - AACR
Loss of DNA mismatch repair occurs in many types of tumors. The effect of the loss of DNA
mismatch repair activity on sensitivity to cisplatin and a panel of analogues was tested using …

Loss of DNA mismatch repair in acquired resistance to cisplatin

S Aebi, B Kurdi-Haidar, R Gordon, B Cenni, H Zheng… - Cancer research, 1996 - AACR
Selection of cells for resistance to cisplatin, a well-recognized mutagen, could result in
mutations in genes involved in DNA mismatch repair and thereby to resistance to DNA-alkylating …

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised …

…, F Boyle, G Jerusalem, R Stahel, S Aebi… - The Lancet …, 2018 - thelancet.com
Background We previously reported the 5-year results of the phase 3 IBCSG 23-01 trial
comparing disease-free survival in patients with breast cancer with one or more micrometastatic (…

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

…, B Ruepp, F Boyle, R Stahel, S Aebi… - The Lancet …, 2019 - thelancet.com
Background HER2-positive breast cancers usually contain large amounts of T-cell infiltrate.
We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be …

[HTML][HTML] Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

…, K Punie, J Fraser, M Nowaczyk, IT Rubio, S Aebi… - Annals of …, 2018 - Elsevier
Background Male breast cancer (BC) is rare, managed by extrapolation from female BC. The
International Male BC Program aims to better characterize and manage this disease. We …

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

S Aebi, T Davidson, G Gruber… - Annals of oncology, 2011 - annalsofoncology.org
… The presence and sizes of the smaller tumor(s) should be recorded using the ‘(m)’ modifier.
… The presence and sizes of the smaller tumor(s) should be recorded using the ‘(m)’ modifier. …

In Vitro and in Vivo Resistance to Cisplatin in Cells That Have Lost DNA Mismatch Repair

D Fink, H Zheng, S Nebel, PS Norris, S Aebi, TP Lin… - Cancer research, 1997 - AACR
In vitro studies have shown that loss of DNA mismatch repair due to lack of either hMSH2 or
hMLH1 activity results in low-level resistance to cisplatin but not to oxaliplatin, an analogue …